CEO Jack Khattar was paid $15,501,557 in fiscal year 2025, ↑ up 22.6% from fiscal year 2024, the 93rd percentile of its disclosed peer group (SEC filing 0001104659-26-053111 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$15,501,557 ↑ Jack Khattar total, FY2025 | 93rd CEO pay percentile vs peers | 81:1 CEO-to-median pay ratio | 96.45% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
SUPN's next annual pay disclosure, estimated April 30, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jack Khattar | $1,036,000 | $0 | $6,535,029 | $7,031,545 | $846,930 | $0 | $52,053 | $15,501,557 |
| Chief Executive Officer, President & Secretary | ||||||||
| Timothy Dec | 504,900 | 0 | 315,040 | 822,429 | 233,894 | 0 | 40,146 | 1,916,409 |
| Senior Vice President, Chief Financial Officer | ||||||||
| Jonathan Rubin | 485,100 | 0 | 315,040 | 411,214 | 197,843 | 0 | 39,534 | 1,448,731 |
| Senior Vice President, Chief Medical Officer Research and Development | ||||||||
| Padmanabh Bhatt | 455,900 | 0 | 315,040 | 411,214 | 168,182 | 0 | 41,093 | 1,391,429 |
| Senior Vice President, Intellectual Property, Chief Scientific Officer | ||||||||
| Frank Mottola | 412,500 | 0 | 315,040 | 411,214 | 173,910 | 0 | 48,037 | 1,360,701 |
| Senior Vice President, Chief Technical Operations Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jack Khattar | $15,501,557 | $12,640,989 | $13,278,093 | ↑ +2,860,568 |
| Timothy Dec | 1,916,409 | 2,277,631 | 2,383,627 | ↓ −361,222 |
| Jonathan Rubin | 1,448,731 | 1,470,066 | 1,587,329 | ↓ −21,335 |
| Padmanabh Bhatt | 1,391,429 | 1,261,551 | 1,468,211 | ↑ +129,878 |
| Frank Mottola | 1,360,701 | 1,334,945 | 1,786,179 | ↑ +25,756 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read SUPERNUS PHARMACEUTICALS, INC.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper SUPN reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the SUPERNUS PHARMACEUTICALS, INC. Peer Teardown Report
$15,501,557 Jack Khattar total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of August 14, 2026 · Source: 0001104659-26-053111 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for SUPN
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order SUPN
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name SUPN as a peer is temporarily unavailable — recheck shortly.
Get the SUPERNUS PHARMACEUTICALS, INC. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Bethany L. Sensenig | Independent Director | $362,513 |
| Carrolee Barlow | Independent Director | $376,013 |
| Charles W. Newhall, III | Chair of the Board | — |
| Frederick M. Hudson | Independent Director | $385,013 |
| Georges Gemayel | Independent Director | $398,513 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2026-07-29 | — | 3,650 | — | — | 3 insiders, 3 accrual rows | ||
| Padmanabh Bhatt | Sr. VP of IP, CSO | 2026-07-29 | A | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack A. Khattar | Director | 2026-07-29 | A | 29,849 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Dec | Senior Vice-President & CFO | 2026-08-12 | A | 1,250 | 0 | 0 | Common | Form 4 ↗ |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 2026-08-12 | A | 1,650 | 0 | 0 | Common | Form 4 ↗ |
| Timothy Dec | Senior Vice-President & CFO | 2026-08-12 | D | 604 | 47 | 28,128 | Common | Form 4 ↗ |
| Padmanabh Bhatt | Sr. VP of IP, CSO | 2026-08-12 | D | 1,158 | 47 | 53,928 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-12 | — | 3,650 | — | — | 3 insiders, 3 accrual rows | ||
| Jonathan Rubin | SVP, Chief Medical Officer | 2026-08-12 | A | 750 | 0 | 0 | Common | Form 4 ↗ |
| Jack A. Khattar | Director | 2026-08-12 | A | 29,849 | 0 | 0 | Common | Form 4 ↗ |
| Padmanabh Bhatt | Sr. VP of IP, CSO | 2026-08-12 | A | 2,500 | 0 | 0 | Common | Form 4 ↗ |
| Jonathan Rubin | SVP, Chief Medical Officer | 2026-08-12 | D | 363 | 47 | 16,905 | Common | Form 4 ↗ |
| Jack A. Khattar | Director | 2026-08-12 | D | 29,849 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack A. Khattar | Director | 2026-08-12 | D | 12,642 | 47 | 588,738 | Common | Form 4 ↗ |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 2026-08-12 | D | 797 | 47 | 37,116 | Common | Form 4 ↗ |
| Padmanabh Bhatt | Sr. VP of IP, CSO | 2026-08-12 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jonathan Rubin | SVP, Chief Medical Officer | 2026-07-29 | A | 750 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Padmanabh Bhatt | Sr. VP of IP, CSO | 2026-07-29 | A | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 2026-07-29 | A | 1,650 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Dec | Senior Vice-President & CFO | 2026-07-29 | A | 1,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack A. Khattar | Director | 2026-07-29 | A | 29,849 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Dec | Senior Vice-President & CFO | 2026-08-12 | A | 1,250 | 0 | 0 | Common | Form 4 ↗ |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 2026-08-12 | A | 1,650 | 0 | 0 | Common | Form 4 ↗ |
| Timothy Dec | Senior Vice-President & CFO | 2026-08-12 | D | 604 | 47 | 28,128 | Common | Form 4 ↗ |
| Padmanabh Bhatt | Sr. VP of IP, CSO | 2026-08-12 | D | 1,158 | 47 | 53,928 | Common | Form 4 ↗ |
| Jonathan Rubin | SVP, Chief Medical Officer | 2026-08-12 | D | 750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jonathan Rubin | SVP, Chief Medical Officer | 2026-08-12 | A | 750 | 0 | 0 | Common | Form 4 ↗ |
| Jack A. Khattar | Director | 2026-08-12 | A | 29,849 | 0 | 0 | Common | Form 4 ↗ |
| Padmanabh Bhatt | Sr. VP of IP, CSO | 2026-08-12 | A | 2,500 | 0 | 0 | Common | Form 4 ↗ |
| Jonathan Rubin | SVP, Chief Medical Officer | 2026-08-12 | D | 363 | 47 | 16,905 | Common | Form 4 ↗ |
| Jack A. Khattar | Director | 2026-08-12 | D | 29,849 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jack A. Khattar | Director | 2026-08-12 | D | 12,642 | 47 | 588,738 | Common | Form 4 ↗ |
| Timothy Dec | Senior Vice-President & CFO | 2026-08-12 | D | 1,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 2026-08-12 | D | 1,650 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Mottola | SVP, Chief Tech. Ops. Officer | 2026-08-12 | D | 797 | 47 | 37,116 | Common | Form 4 ↗ |
| Padmanabh Bhatt | Sr. VP of IP, CSO | 2026-08-12 | D | 2,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Timothy Dec | PSU | 2025-02-19 | — | 4,500 | — | 4,500 | $150,840 |
| Timothy Dec | PSU | 2025-05-03 | — | 5,000 | — | 5,000 | 164,200 |
| Padmanabh Bhatt | PSU | 2025-05-03 | — | 5,000 | — | 5,000 | 164,200 |
| Jonathan Rubin | PSU | 2025-05-03 | — | 5,000 | — | 5,000 | 164,200 |
| Frank Mottola | PSU | 2025-02-19 | — | 4,500 | — | 4,500 | 150,840 |
| Frank Mottola | PSU | 2025-05-03 | — | 5,000 | — | 5,000 | 164,200 |
| Jonathan Rubin | PSU | 2025-02-19 | — | 4,500 | — | 4,500 | 150,840 |
| Jack Khattar | PSU | 2025-05-03 | — | 198,996 | — | 198,996 | 6,535,029 |
| Timothy Dec | PSU | 2025-02-19 | — | 40,000 | — | 40,000 | 822,429 |
| Jack Khattar | PSU | 2025-02-20 | — | 331,660 | — | 331,660 | 7,031,544 |
| Jonathan Rubin | PSU | 2025-02-19 | — | 20,000 | — | 20,000 | 411,214 |
| Padmanabh Bhatt | PSU | 2025-02-19 | — | 4,500 | — | 4,500 | 150,840 |
| Padmanabh Bhatt | PSU | 2025-02-19 | — | 20,000 | — | 20,000 | 411,214 |
| Frank Mottola | PSU | 2025-02-19 | — | 20,000 | — | 20,000 | 411,214 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Timothy Dec | $0 | $1,137,469 | $0 | 100.0% |
| Padmanabh Bhatt | 0 | 726,254 | 0 | 100.0% |
| Jonathan Rubin | 0 | 726,254 | 0 | 100.0% |
| Frank Mottola | 0 | 726,254 | 0 | 100.0% |
| Jack Khattar | 0 | 13,566,573 | 0 | 100.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Frank Mottola | RSU | 3,750 | — | $186,375 |
| Jack Khattar | Option | 241,500 | 27.94 | — |
| Frank Mottola | Option | 20,000 | 33.52 | — |
| Padmanabh Bhatt | PSU | 3,350 | — | 166,495 |
| Frank Mottola | Option | 18,750 | 27.94 | — |
| Jonathan Rubin | RSU | 750 | — | 37,275 |
| Jack Khattar | Option | 331,660 | 34.59 | — |
| Padmanabh Bhatt | Option | 15,000 | 27.94 | — |
| Padmanabh Bhatt | RSU | 4,500 | — | 223,650 |
| Timothy Dec | RSU | 9,000 | — | 447,300 |
| Timothy Dec | Option | 37,500 | 27.94 | — |
| Frank Mottola | Option | 15,000 | 38.6 | — |
| Timothy Dec | RSU | 500 | — | 24,850 |
| Frank Mottola | PSU | 5,000 | — | 248,500 |
| Padmanabh Bhatt | RSU | 3,750 | — | 186,375 |
| Frank Mottola | Option | 4,500 | 32.2 | — |
| Jack Khattar | PSU | 96,600 | — | 4,801,020 |
| Padmanabh Bhatt | RSU | 2,500 | — | 124,250 |
| Jonathan Rubin | Option | 6,250 | 32.2 | — |
| Jack Khattar | PSU | 198,996 | — | 9,890,101 |
| Padmanabh Bhatt | Option | 10,000 | 38.6 | — |
| Timothy Dec | PSU | 10,200 | — | 506,940 |
| Timothy Dec | RSU | 5,000 | — | 248,500 |
| Timothy Dec | RSU | 4,500 | — | 223,650 |
| Frank Mottola | PSU | 3,750 | — | 186,375 |
| Timothy Dec | PSU | 5,000 | — | 248,500 |
| Jonathan Rubin | PSU | 5,000 | — | 248,500 |
| Jonathan Rubin | PSU | 3,000 | — | 149,100 |
| Jack Khattar | Option | 62,500 | 32.2 | — |
| Padmanabh Bhatt | PSU | 5,000 | — | 248,500 |
| Jonathan Rubin | RSU | 4,500 | — | 223,650 |
| Padmanabh Bhatt | Option | 4,500 | 32.2 | — |
| Padmanabh Bhatt | Option | 20,000 | 33.52 | — |
| Frank Mottola | RSU | 4,500 | — | 223,650 |
| Jonathan Rubin | Option | 10,000 | 38.6 | — |
| Jonathan Rubin | RSU | 3,750 | — | 186,375 |
| Jonathan Rubin | RSU | 2,500 | — | 124,250 |
| Padmanabh Bhatt | RSU | 750 | — | 37,275 |
| Timothy Dec | Option | 20,000 | 38.6 | — |
| Frank Mottola | RSU | 750 | — | 37,275 |
| Jack Khattar | Option | 140,000 | 38.6 | — |
| Timothy Dec | Option | 6,250 | 32.2 | — |
| Jonathan Rubin | Option | 18,750 | 27.94 | — |
| Timothy Dec | Option | 40,000 | 33.52 | — |
| Jonathan Rubin | Option | 20,000 | 33.52 | — |
The executive compensation program is designed to align the interests of NEOs with stockholders by rewarding executives with incentives closely linked to the achievement of short-term and long-term business objectives. The program aims to attract and retain highly qualified executives by providing competitive compensation levels relative to comparably sized pharmaceutical and biotechnology companies.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 45,552,633 | 1,675,355 | 7,714 | 96.45% | Passed |
| 2025 | 2025-06-16 | 45,796,936 | 1,701,777 | 33,212 | 96.42% | Passed |
| 2024 | 2024-06-14 | 48,217,539 | 2,290,237 | 24,309 | 95.47% | Passed |
| 2023 | 2023-06-16 | 47,347,143 | 1,453,112 | 14,525 | 97.02% | Passed |
| 2022 | 2022-06-17 | 45,856,924 | 832,225 | 161,801 | 98.22% | Passed |
| 2021 | 2021-06-15 | 42,838,972 | 1,011,042 | 245,862 | 97.69% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-18 | 96.45%a |
| 2025 | 2025-06-16 | 96.42%b |
| 2024 | 2024-06-14 | 95.47%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of the vote with respect to Proposals 2, 3, and 4 and broker non-votes will have no effect on the outcome of these proposals.”.
b. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of the vote with respect to Proposals 2 and 3, and broker non-votes will have no effect on the outcome of these proposals.”.
c. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of the vote with respect to Proposals 2, 3 and 4, and broker non-votes will have no effect on the outcome of these proposals.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 81 : 1 |
|---|---|
| CEO total compensation | $15,501,557 |
| Median employee compensation | $192,397 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Charles W. Newhall IIIIndependent · Board Chair · Governance and Nominating (Chair) · Compensation | $117,000 | $150,002 | $150,011 | $0 | $0 | $417,013 |
| Georges GemayelIndependent · Audit · Compensation (Chair) · Governance and Nominating · Science | 98,500 | 150,002 | 150,011 | 0 | 0 | 398,513 |
| Frederick M. HudsonIndependent · Audit (Chair) · Compensation | 85,000 | 150,002 | 150,011 | 0 | 0 | 385,013 |
| Carrolee BarlowIndependent · Governance and Nominating · Science (Chair) · Partial-year service | 76,000 | 150,002 | 150,011 | 0 | 0 | 376,013 |
| Bethany L. SensenigIndependent · Audit | 62,500 | 150,002 | 150,011 | 0 | 0 | 362,513 |
| Jack A. KhattarEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,000 |
| Stock ownership guideline | to support the Company’s share ownership guidelines for members of the Board of Directors. |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $439,000 |
| Equity awards (grant-date value) | $750,010 |
| All other compensation | $0 |
| Total cost of the board | $1,189,010 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies SUPERNUS PHARMACEUTICALS, INC. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including SUPERNUS PHARMACEUTICALS, INC..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | PTC Therapeutics, Inc. | 2025 | Matthew Klein | $958,500 | $16,593,800 | $4,399,760 | $1,294,000 | $23,266,326 |
| 2 | SUPERNUS PHARMACEUTICALS, INC. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 3 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 4 | Pacira Biosciences, Inc. | 2025 | Frank Lee | 935,308 | 9,215,500 | 0 | 738,810 | 11,636,917 |
| 5 | Ligand Pharmaceuticals Incorporated | 2025 | Todd Davis | 724,500 | 5,520,493 | 4,441,120 | 764,400 | 11,472,095 |
| 6 | Ultragenyx Pharmaceutical Inc. | 2025 | Emil Kakkis | 861,100 | 8,364,938 | 1,847,356 | 299,663 | 11,405,535 |
| 7 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 8 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 9 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 10 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 11 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 12 | Dynavax Technologies Corporation | 2024 | Ryan Spencer | 835,001 | 4,902,150 | 1,824,299 | 641,907 | 8,210,775 |
| 13 | Harmony Biosciences Holdings, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 14 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 15 | Xeris Biopharma Holdings, Inc. | 2025 | John Shannon | 742,334 | 2,848,000 | 838,615 | 607,971 | 5,042,584 |
| 16 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC. | not disclosed | not disclosed | No | Aon |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Catalyst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Dynavax Technologies Corporation | 102.5% | Options 34 · RSU 33 · PSU 33 | Yes — Relative Total Stockholder Return (rTSR) ranking vs. Nasdaq Biotechnology Index | Alpine |
| Harmony Biosciences Holdings, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Ligand Pharmaceuticals Incorporated | 150% | not disclosed | No | Aon |
| Pacira Biosciences, Inc. | 90% | RSU 80 · PSU 20 | No | Aon |
| PTC Therapeutics, Inc. | not disclosed | Option 50 · RSU 50 | Yes — TSR relative to Nasdaq Biotechnology Index | Frederic W. Cook & Co., Inc. |
| Ultragenyx Pharmaceutical Inc. | 44% | PSU 60 · RSU 20 · Options 20 | Yes — Relative TSR | Aon's Human Capital Solutions Practice |
| Xeris Biopharma Holdings, Inc. | 125% | not disclosed | not disclosed | Aon Consulting, Inc. |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jack Khattar | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Executive Compensation”. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 2 | Section 01, Timothy Dec | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Executive Compensation”. As printed: 1,916,409. Filing ↗machine: r4 · c41 · span 443159–443168 |
| 3 | Section 01, Jonathan Rubin | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Executive Compensation”. As printed: 1,448,731. Filing ↗machine: r7 · c41 · span 455765–455774 |
| 4 | Section 01, Padmanabh Bhatt | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Executive Compensation”. As printed: 1,391,429. Filing ↗machine: r10 · c41 · span 468264–468273 |
| 5 | Section 01, Frank Mottola | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Executive Compensation”. As printed: 1,360,701. Filing ↗machine: r13 · c41 · span 480684–480693 |
| 6 | Section 03, Timothy Dec PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 554008–554015 |
| 7 | Section 03, Timothy Dec PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 559652–559659 |
| 8 | Section 03, Padmanabh Bhatt PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 604345–604352 |
| 9 | Section 03, Jonathan Rubin PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 581995–582002 |
| 10 | Section 03, Frank Mottola PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 621055–621062 |
| 11 | Section 03, Frank Mottola PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 626865–626872 |
| 12 | Section 03, Jonathan Rubin PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 576351–576358 |
| 13 | Section 03, Jack Khattar PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 537311–537320 |
| 14 | Section 03, Timothy Dec PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 548503–548510 |
| 15 | Section 03, Jack Khattar PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 531661–531670 |
| 16 | Section 03, Jonathan Rubin PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 570846–570853 |
| 17 | Section 03, Padmanabh Bhatt PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 598701–598708 |
| 18 | Section 03, Padmanabh Bhatt PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 593196–593203 |
| 19 | Section 03, Frank Mottola PSU | DEF 14A | 1900-01-01 | 0001104659-26-053111 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 615542–615549 |
| 20 | Section 07, pay ratio | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “CEO Pay Ratio”. As printed: 81 : 1. Filing ↗ |
| 21 | Section 08, Charles W. Newhall III | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Director Compensation”. As printed: 417,013. Filing ↗machine: span 1236166–1236173 |
| 22 | Section 08, Georges Gemayel | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Director Compensation”. As printed: 398,513. Filing ↗machine: span 1230522–1230529 |
| 23 | Section 08, Frederick M. Hudson | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Director Compensation”. As printed: 385,013. Filing ↗machine: span 1233329–1233336 |
| 24 | Section 08, Carrolee Barlow | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Director Compensation”. As printed: 376,013. Filing ↗machine: span 1238982–1238989 |
| 25 | Section 08, Bethany L. Sensenig | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Director Compensation”. As printed: 362,513. Filing ↗machine: span 1241814–1241821 |
| 26 | Section 08, Jack A. Khattar | DEF 14A | 2026-04-30 | 0001104659-26-053111 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 27 | Section 02, Jonathan Rubin 2026-07-29 | Form 4 | 2026-07-31 | 0001836067-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Padmanabh Bhatt 2026-07-29 | Form 4 | 2026-07-31 | 0001539215-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Frank Mottola 2026-07-29 | Form 4 | 2026-07-31 | 0001804567-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Timothy Dec 2026-07-29 | Form 4 | 2026-07-31 | 0001194020-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Jack A. Khattar 2026-07-29 | Form 4 | 2026-07-31 | 0001539937-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Timothy Dec 2026-08-12 | Form 4 | 2026-08-14 | 0001194020-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Frank Mottola 2026-08-12 | Form 4 | 2026-08-14 | 0001804567-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Timothy Dec 2026-08-12 | Form 4 | 2026-08-14 | 0001194020-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Padmanabh Bhatt 2026-08-12 | Form 4 | 2026-08-14 | 0001539215-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Jonathan Rubin 2026-08-12 | Form 4 | 2026-08-14 | 0001836067-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Jonathan Rubin 2026-08-12 | Form 4 | 2026-08-14 | 0001836067-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Jack A. Khattar 2026-08-12 | Form 4 | 2026-08-14 | 0001539937-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Padmanabh Bhatt 2026-08-12 | Form 4 | 2026-08-14 | 0001539215-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Jonathan Rubin 2026-08-12 | Form 4 | 2026-08-14 | 0001836067-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Jack A. Khattar 2026-08-12 | Form 4 | 2026-08-14 | 0001539937-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Jack A. Khattar 2026-08-12 | Form 4 | 2026-08-14 | 0001539937-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Timothy Dec 2026-08-12 | Form 4 | 2026-08-14 | 0001194020-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Frank Mottola 2026-08-12 | Form 4 | 2026-08-14 | 0001804567-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Frank Mottola 2026-08-12 | Form 4 | 2026-08-14 | 0001804567-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Padmanabh Bhatt 2026-08-12 | Form 4 | 2026-08-14 | 0001539215-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 06, 2026 vote | Form 8-K | 2026-06-18 | 0001356576-26-000028 | Item 5.07 · say-on-pay result. As reported: 96.45% (votes for as printed: 45,552,633). Filing ↗ |
| 48 | Section 06, 2025 vote | Form 8-K | 2025-06-17 | 0001356576-25-000042 | Item 5.07 · say-on-pay result. As reported: 96.42% (votes for as printed: 45,796,936). Filing ↗ |
| 49 | Section 06, 2024 vote | Form 8-K | 2024-06-17 | 0001104659-24-072272 | Item 5.07 · say-on-pay result. As reported: 95.47% (votes for as printed: 48,217,539). Filing ↗ |
| 50 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 51 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 52 | Section 09b board cost (computed) | Computed | — | — | Cash 439,000 + equity 750,010 + all other 0 = 1,189,010, summed across the director compensation table rows.machine: formula: Σ = 1,189,010 |
| 53 | PTC Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045528 | CEO total compensation as printed in PTC Therapeutics, Inc.'s own proxy. As printed: 23,266,326. Filing ↗ |
| 54 | SUPERNUS PHARMACEUTICALS, INC. (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in SUPERNUS PHARMACEUTICALS, INC.'s own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 55 | Corcept Therapeutics Incorporated, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 56 | Pacira Biosciences, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001104659-26-050353 | CEO total compensation as printed in Pacira Biosciences, Inc.'s own proxy. As printed: 11,636,917. Filing ↗machine: t136 · r1 · c47 · span 2412158–2412168 |
| 57 | Ligand Pharmaceuticals Incorporated, Section 10b CEO total | DEF 14A | 2026-04-21 | 0000886163-26-000021 | CEO total compensation as printed in Ligand Pharmaceuticals Incorporated's own proxy. As printed: 11,472,095. Filing ↗machine: span 722741–722751 |
| 58 | Ultragenyx Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0001308179-26-000174 | CEO total compensation as printed in Ultragenyx Pharmaceutical Inc.'s own proxy. As printed: 11,405,535. Filing ↗machine: span 668997–669007 |
| 59 | Axsome Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 60 | ANI Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001023024-26-000039 | CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154 |
| 61 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 62 | Amphastar Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-13 | 0001297184-26-000023 | CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. Filing ↗machine: span 722923–722932 |
| 63 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 64 | Dynavax Technologies Corporation, Section 10b CEO total | DEF 14A | 2025-04-17 | 0000930413-25-001273 | CEO total compensation as printed in Dynavax Technologies Corporation's own proxy. As printed: 8,210,775. Filing ↗ |
| 65 | Harmony Biosciences Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-03 | 0001104659-26-039449 | CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. Filing ↗machine: t108 · r5 · c16 · span 580355–580364 |
| 66 | Catalyst Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. Filing ↗ |
| 67 | Xeris Biopharma Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001867096-26-000021 | CEO total compensation as printed in Xeris Biopharma Holdings, Inc.'s own proxy. As printed: 5,042,584. Filing ↗machine: r3 · c42 · span 463532–463541 |
| 68 | Collegium Pharmaceutical, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 69 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc. names SUPERNUS PHARMACEUTICALS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 70 | Section 10a, ANI Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001023024-26-000039 | ANI Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include SUPERNUS PHARMACEUTICALS, INC.. Filing ↗ |
| 71 | Section 10a, Axsome Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include SUPERNUS PHARMACEUTICALS, INC.. Filing ↗ |
| 72 | Section 10a, Dynavax Technologies Corporation reciprocity | DEF 14A | — | 0000930413-25-001273 | Dynavax Technologies Corporation names SUPERNUS PHARMACEUTICALS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 73 | Section 10a, PTC Therapeutics, Inc. reciprocity | DEF 14A | — | 0001104659-26-045528 | PTC Therapeutics, Inc. names SUPERNUS PHARMACEUTICALS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 74 | Section 10a, Harmony Biosciences Holdings, Inc. reciprocity | DEF 14A | — | 0001104659-26-039449 | Harmony Biosciences Holdings, Inc. names SUPERNUS PHARMACEUTICALS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 75 | Section 10a, Ultragenyx Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001308179-26-000174 | Ultragenyx Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include SUPERNUS PHARMACEUTICALS, INC.. Filing ↗ |
| 76 | Section 10a, Ligand Pharmaceuticals Incorporated reciprocity | DEF 14A | — | 0000886163-26-000021 | Ligand Pharmaceuticals Incorporated's most recent proxy was read; its disclosed peer group does not include SUPERNUS PHARMACEUTICALS, INC.. Filing ↗ |
| 77 | Section 10a, Catalyst Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001193125-25-079097 | Catalyst Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include SUPERNUS PHARMACEUTICALS, INC.. Filing ↗ |
| 78 | Section 10a, Xeris Biopharma Holdings, Inc. reciprocity | DEF 14A | — | 0001867096-26-000021 | Xeris Biopharma Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include SUPERNUS PHARMACEUTICALS, INC.. Filing ↗ |
| 79 | Section 10a, Collegium Pharmaceutical, Inc. reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceutical, Inc.'s most recent proxy was read; its disclosed peer group does not include SUPERNUS PHARMACEUTICALS, INC.. Filing ↗ |
| 80 | Section 10a, Pacira Biosciences, Inc. reciprocity | DEF 14A | — | 0001104659-26-050353 | Pacira Biosciences, Inc. names SUPERNUS PHARMACEUTICALS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 81 | Section 10a, Amphastar Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001297184-26-000023 | Amphastar Pharmaceuticals, Inc. names SUPERNUS PHARMACEUTICALS, INC. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include SUPERNUS PHARMACEUTICALS, INC.. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the SUPERNUS PHARMACEUTICALS, INC. Executive Compensation Report
$1,500